Tern’s portfolio company Wyld Networks signs contract with Bayer Crop Science

IoT

Tern Plc (LON:TERN), the investment company specialising in the Internet of Things, has noted that its portfolio company Wyld Networks AB has announced that it has signed a contract with Bayer Crop Science, a world leader in agriculture and part of the multinational Bayer Corporation.  Bayer has placed an initial purchase order worth SEK 320,000 (approximately £27,000) with Wyld Networks to develop a satellite IoT terminal and sensor to collect data from beehives.

Commenting Al Sisto, CEO of Tern, said:

“This is an important engagement for Wyld and we are very pleased that they are now working to develop a satellite IoT platform with Bayer. As Wyld’s CEO Alastair Williamson has pointed out, there is a substantial and growing market for affordable satellite IoT connectivity in multiple markets from agriculture, utilities, maritime and the environment and we look forward to Wyld’s continued progress”.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines uses AI to turn medical congress discussions into pharma insights

Talking Medicines uses AI to analyse healthcare professional conversations at medical congresses, turning discussions into structured insights that help...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

Device Authority warns supermarket freezer cyberattack exposes connected device security risks

Device Authority warns that a cyberattack affecting around 700 French supermarkets exposes security weaknesses in connected industrial equipment and...

Breast cancer research highlights importance of patient intelligence in pharma

Talking Medicines highlights how AI-powered patient intelligence can help pharmaceutical companies understand breast cancer treatment experiences and identify unmet...

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Search